Tuesday, May 10, 2011 1:53:55 PM
There is an established relationship that can’t be ignored between BOCL, ACLH, and BCLE and/or their executive management, officers, consultants, directors, and it has been reported by public PR’s and published financial statements that they have a substantial amount of stock holdings in each other.
Wagley Oil & Gas Inc, a recently announced BOCL joint venture partner, is a Texas business only formed on March 14, 2011 and not a well establish and prolific business entity either. A director of this company is Tim Connolly, Russell Kidder’s cohort and long time associate in many OTC Market companies, who played an important role in ACLH as a consultant for Corporate Strategies Inc.
BOCL may be following the same pattern with the same individuals who continually produced, hyped, and promoted deceptive PR’s for BCLE and ACLH which led to their difficulties, ACLH’s SEC sanction and grey market status, BCLE management departures, stock sell offs after the pumping of the stock through friendly market-makers, transferring of assets, and subsequent questionable joint ventures, reorganizations, and name changes.
There was little concern for the shareholders of BCLE and ACLH who have suffered losses in the hundreds of thousands of dollars. These relationships do not inspire confidence in BOCL, whatever their motives may be, and their willingness and/or ability to succeed in the long run. Since BOCL is the only reporting company of the group, Mr. Marchi has the burden to keep their shareholders and the public honestly informed, answer all questions about the company, and to provide further explanation about current and/or past relationships with BCLE and ACLH which he continues to ignore.
IMO, all the “traders” may make a few dollars on the bounces and dips created by devious market-makers, but for all you “investors”, be aware of these relationships and consider placing your money elsewhere. All the information presented is contained in the public record and can be obtained by anyone doing proper due diligence for the above companies and their management personnel. GLTA
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM